<DOC>
	<DOCNO>NCT02178254</DOCNO>
	<brief_summary>The objective determine safety , tolerability pharmacokinetics ( PK ) 2 single dos ZTI-01 ( 1g 8g infused 1-hr ) single dose Reference Label Drug , Monurol® ( oral sachet , 3g ) . Subjects randomized treatment sequence prior dose Day 1 Period 1 prior study screening .</brief_summary>
	<brief_title>Safety , Tolerability PK 3-Period Crossover Study Comparing 2 Single Doses ZTI-01 Monurol® Healthy Subjects</brief_title>
	<detailed_description>This Phase 1 single-dose , randomize , 3-Period , crossover study conduct single center . A total 30 healthy subject , age 18-45years , randomize receive one 3 treatment sequence . The duration study approximately 18-26 day subject participation duration study . Each treatment sequence enrol parallel subject receive 3 treatment crossover fashion . Each subject complete Screening , Baseline , Treatment Phases . The Screening Phase conduct outpatient basis within 35 day admission ( Day -1 Period 1 ) . All subject admit study center day dose treatment period ( Day -1 ; check-in ) pre-dosing assessment remain study center 48 hour post-dose Period . Final baseline qualification evaluate prior randomization Treatment Period 1 . Each one period separate 3 ( minimum ) 7 day ( maximum ) washout period . The Treatment Phase comprise 3 crossover period ( duration Day-1 48 hour post dose ) . Each crossover period include single dose study drug fast condition follow post-dose safety assessment blood urine collection PK measure 48 hour post-dose ; period separate 3 7 day washout . Subjects remain study center 3- study treatment period ( Day -1 48 hour post dose ) discharge 48-hour sampling timepoint ( safety parameter acceptable Investigator Day 3 ) .</detailed_description>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>To consider study enrollment , subject must meet inclusion criterion : Healthy men woman 18 45 year age clinically significant finding medical history , physical examination , vital sign , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation perform Screening Day 1 . Body Mass Index ( BMI ) 1830 kg/m^2 , inclusive ; total body weight &gt; 50 kg ( 110 lb ) . Postmenopausal woman amenorrhea least 2 year FSH postmenopausal range well surgically sterile woman ( documented history oophorectomy and/or hysterectomy , tubal ligation tubal occlusion ) eligible . Females childbearing potential must use acceptable birth control method ( e.g. , condom plus spermicide , combined oral contraceptive , implant , injectable , indwell intrauterine device , sexual abstinence , vasectomized partner ) throughout study 4 week follow initiation dose study drug . Male subject must either vasectomy agree use double barrier method contraception , condom plus spermicide ( diaphragm plus spermicide female partner ) time dose study drug Period 1 4 week follow initiation dose study drug . Nicotinefree history ( cigarette , pipe , cigar , chew tobacco , nicotine patch ) least 30 day Day 1 urine cotinine prestudy screen Day 1 &lt; 400 ng/mL ) . Able abstain grapefruit , grapefruit juice , grapefruitcontaining product alcoholic beverage within 48 hour Day 1 throughout inpatient period . Willing remain study facility agree abide Quintiles Phase 1 Unit House Rules duration inpatient study period . Have high probability compliance completion study . Sign date , witness , write informed consent form Subjects must meet none follow study criterion Study Day 1 , Period 1 : History presence psychiatric emotional disorder might prevent successful completion study . Any surgical medical condition opinion investigator could interfere drug absorption , distribution , metabolism , excretion condition may place subject increase risk participate study . Examples condition exclusion : previous bariatric surgery , cardiovascular disease , renal impairment , renal disease , liver disease , chronic pulmonary disease , venous insufficiency , peripheral edema , borderline hypertension systolic pressure &gt; 140mmHg diastolic pressure &gt; 90 mmHg , serum sodium liver enzymes upper limit , Regarding last two condition , one repeat allow screen checkin determine eligibility . Any history presence clinically significant allergic condition ( e.g. , recurrent dermatitis drug hypersensitivity reaction ) . Have cancer history cancer ( exception type cancer , e.g . recent removal basal cell skin carcinoma ) within past five year . Irritable bowel syndrome gastrointestinal disease ( include frequent nausea due migraine ) within 30 day prior study day 1 , Period 1 . History presence lactose intolerance . History alcohol abuse within 12 month study day 1 , Period 1 . History intolerance hypersensitivity phosphonic acid derivative antibiotic constituent Use prescription drug within 30 day administration study drug Involvement investigational study type ( drug , device , procedure ) within 30 day screen . Blood blood product donation within 60 day Day 1 . Use nonprescription medication , vitamin , licorice ( large amount ) dietary supplement within 7 day administration study drug . Excluded list intermittent use acetaminophen dose &lt; /=2 g/day . Herbal supplement must discontinue 7 day prior initial dose study drug . Consumption 300 mg caffeine per day ( &gt; 3 cup coffee 612 ounce soda ) within 7 day prior dose . Presence acute illness within 7 day Day 1 Study Period . Breastfeeding positive serum pregnancy test Screening Visit Day 1 Study Period Positive test human immunodeficiency virus ( HIV 1 2 ) antibody , hepatitis B surface antigen ( HBsAg ) and/or hepatitis C ( HCV ) antibody . Positive urine drug alcohol screen Screening Visit Day 1 Weight loss gain &gt; 10 percent within 30 day Day 1 . Females whose hemoglobin &lt; 11.8 g/dL male whose hemoglobin &lt; 13.8g/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Pseudomonas aeruginosa , ZTI-101 , phosphonic acid derivative , Monurol , fosfomycin tromethamine</keyword>
</DOC>